CL2004000573A1 - Composicion farmaceutica que comprende un aceite anfipatico, cera microcristalina y un vehiculo no acuoso, donde dicho vehiculo tiene disperso un agente antiinflamatorio, y su uso para tratar y/o prevenir una afeccion inflamatoria en un organo que co - Google Patents

Composicion farmaceutica que comprende un aceite anfipatico, cera microcristalina y un vehiculo no acuoso, donde dicho vehiculo tiene disperso un agente antiinflamatorio, y su uso para tratar y/o prevenir una afeccion inflamatoria en un organo que co

Info

Publication number
CL2004000573A1
CL2004000573A1 CL200400573A CL2004000573A CL2004000573A1 CL 2004000573 A1 CL2004000573 A1 CL 2004000573A1 CL 200400573 A CL200400573 A CL 200400573A CL 2004000573 A CL2004000573 A CL 2004000573A CL 2004000573 A1 CL2004000573 A1 CL 2004000573A1
Authority
CL
Chile
Prior art keywords
vehicle
inflammatory
amphipatic
oil
pharmaceutical composition
Prior art date
Application number
CL200400573A
Other languages
English (en)
Inventor
J Britten John W Hallber Nancy
Original Assignee
Pharmacia Corp Sa Organizada B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp Sa Organizada B filed Critical Pharmacia Corp Sa Organizada B
Publication of CL2004000573A1 publication Critical patent/CL2004000573A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

USO DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN AGENTE ANTIINFLAMATORIO Y UN VEHICULO QUE COMPRENDE UN ACEITE ANFIPATICO QUE ES DISPERSABLE EN AGUA E INSOLUBLE EN ETANOL, CERA MICROCRISTALINA Y UN VEHICULO NO ACUOSO FARMACEUTICAMENTE ACEPTABLE, Y QUE ADEMAS COMPRENDE UN AGENTE ANTIINFLAMATORIO, PARA EL TRATAMIENTO DE UNA AFECCION ANTIINFLAMATORIA EN UN ORGANO QUE CONTIENEN FLUIDO QUE TIENEN UN ORIFICIO NATURAL EXTERIOR, TAL COMO LA UBRE DE UN ANIMAL PRODUCTOR DE LECHE O UN OIDO, DICHA COMPOSICION SE APLICA AL ORGANO A TRAVES DEL ORIFICO EXTERIOR.
CL200400573A 2003-03-20 2004-03-19 Composicion farmaceutica que comprende un aceite anfipatico, cera microcristalina y un vehiculo no acuoso, donde dicho vehiculo tiene disperso un agente antiinflamatorio, y su uso para tratar y/o prevenir una afeccion inflamatoria en un organo que co CL2004000573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45632503P 2003-03-20 2003-03-20

Publications (1)

Publication Number Publication Date
CL2004000573A1 true CL2004000573A1 (es) 2005-01-14

Family

ID=33030094

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400573A CL2004000573A1 (es) 2003-03-20 2004-03-19 Composicion farmaceutica que comprende un aceite anfipatico, cera microcristalina y un vehiculo no acuoso, donde dicho vehiculo tiene disperso un agente antiinflamatorio, y su uso para tratar y/o prevenir una afeccion inflamatoria en un organo que co

Country Status (26)

Country Link
US (1) US20040235803A1 (es)
EP (1) EP1608407B1 (es)
JP (1) JP2006520779A (es)
KR (1) KR100717433B1 (es)
CN (1) CN1761487A (es)
AR (1) AR043650A1 (es)
AT (1) ATE337793T1 (es)
AU (1) AU2004222523A1 (es)
BR (1) BRPI0408556A (es)
CA (1) CA2519125A1 (es)
CL (1) CL2004000573A1 (es)
CO (1) CO5611169A2 (es)
CY (1) CY1105652T1 (es)
DE (1) DE602004002201T2 (es)
DK (1) DK1608407T3 (es)
ES (1) ES2270361T3 (es)
MX (1) MXPA05009978A (es)
NO (1) NO20054260L (es)
PL (1) PL1608407T3 (es)
PT (1) PT1608407E (es)
RU (1) RU2325189C2 (es)
SI (1) SI1608407T1 (es)
TW (1) TWI262084B (es)
UY (1) UY28235A1 (es)
WO (1) WO2004082588A2 (es)
ZA (1) ZA200506920B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
RU2323019C1 (ru) * 2006-11-23 2008-04-27 Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию Способ лечения больных с посттравматической сенсоневральной тугоухостью в остром периоде, возникшей в результате минно-взрывной травмы
RU2356556C1 (ru) * 2007-11-21 2009-05-27 ФГОУ ВПО Уральская государственная сельскохозяйственная академия (УрГСХА), ОНРИ Средство для лечения воспалений и травм молочной железы у коров
WO2010036427A1 (en) 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
KR20140063616A (ko) 2011-07-20 2014-05-27 브라이엄 영 유니버시티 소수성 세라게닌 화합물 및 이를 포함하는 기구
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
EP3449900A1 (en) 2011-12-21 2019-03-06 Brigham Young University Oral care compositions
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
RU2486905C1 (ru) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Средство для лечения мастита у животных
CA2888259C (en) * 2012-10-17 2019-05-28 Brigham Young University Treatment and prevention of mastitis
AU2014203882B2 (en) 2013-01-07 2016-06-23 Brigham Young University Methods for reducing cellular proliferation and treating certain diseases
MX375254B (es) * 2013-02-08 2025-03-06 Luoda Pharma Ltd Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis.
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
BR112015023747B1 (pt) 2013-03-15 2023-04-18 Brigham Young University Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB2584034B (en) 2013-12-20 2021-03-24 Harvard College Organomimetic devices and methods of use and manufacturing thereof
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
RU2557691C1 (ru) * 2014-07-25 2015-07-27 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический Центр оториноларингологии им Л.И. Свержевского" Департамента здравоохранения города Москвы Способ определения длительности лечения активных форм отосклероза
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104688554A (zh) * 2015-01-30 2015-06-10 柳州两面针股份有限公司 水杨苷在制备口腔护理保健品中的应用
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
KR101625020B1 (ko) 2016-02-11 2016-06-01 최예도 식기세척기
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
KR102099363B1 (ko) * 2017-09-08 2020-04-10 동국제약 주식회사 아보카도 오일 분획을 유효성분으로 포함하는 난청의 예방 또는 치료용 약학적 조성물
EP3603645B1 (en) 2018-07-30 2024-08-07 Virbac Novel use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
CN121129820A (zh) * 2025-10-15 2025-12-16 广州大光制药有限公司 一种含苯胺洛芬的耳用制剂组合物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1181527A (en) * 1966-09-21 1970-02-18 Douglas Gabriel Parizeau Composition and Method for Treating Mastitis with Therapeutic Agents.
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) * 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
US4299501A (en) * 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
IT1190445B (it) * 1985-11-08 1988-02-16 Fatro Spa Composizioni veterinarie a base di agenti antimicrobici e loro impiego
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CA2222138C (en) * 1995-05-25 2008-10-14 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
WO1996039146A1 (en) * 1995-06-06 1996-12-12 Bayer Corporation Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
ATE249206T1 (de) * 1997-12-03 2003-09-15 Merck & Co Inc Langwirkende, injizierbare, formulierungen enthaltend rizinusöl
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
JP2003523958A (ja) * 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
WO2001072298A1 (en) * 2000-03-27 2001-10-04 The General Hospital Corporation Treatments for immune-mediated ear disorders
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
EP1353664A2 (en) * 2000-06-08 2003-10-22 The Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use

Also Published As

Publication number Publication date
RU2005129266A (ru) 2006-03-20
UY28235A1 (es) 2004-11-08
CA2519125A1 (en) 2004-09-30
ZA200506920B (en) 2007-09-26
EP1608407A2 (en) 2005-12-28
DE602004002201D1 (de) 2006-10-12
MXPA05009978A (es) 2005-11-04
DK1608407T3 (da) 2006-12-04
NO20054260L (no) 2005-12-12
WO2004082588A2 (en) 2004-09-30
AU2004222523A1 (en) 2004-09-30
CN1761487A (zh) 2006-04-19
US20040235803A1 (en) 2004-11-25
BRPI0408556A (pt) 2006-03-21
CO5611169A2 (es) 2006-02-28
NO20054260D0 (no) 2005-09-15
SI1608407T1 (sl) 2006-12-31
CY1105652T1 (el) 2010-12-22
TW200503756A (en) 2005-02-01
WO2004082588A3 (en) 2004-12-23
RU2325189C2 (ru) 2008-05-27
JP2006520779A (ja) 2006-09-14
PL1608407T3 (pl) 2006-12-29
EP1608407B1 (en) 2006-08-30
TWI262084B (en) 2006-09-21
DE602004002201T2 (de) 2007-09-20
ATE337793T1 (de) 2006-09-15
KR20050114249A (ko) 2005-12-05
KR100717433B1 (ko) 2007-05-14
ES2270361T3 (es) 2007-04-01
PT1608407E (pt) 2006-12-29
AR043650A1 (es) 2005-08-03

Similar Documents

Publication Publication Date Title
UY28235A1 (es) Formulación dispersable de un agente antiinflamatorio
AR043651A1 (es) Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos
ES2184679T3 (es) Composicion de gel y su uso en composiciones cosmeticas y similares.
AR036266A1 (es) Pelicula para refrescar el aliento
DE60020098D1 (de) Flüssige polymerdispersionen, ihre herstellung und verwendung
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
AR054227A1 (es) Composicion de principios activos
TW200716198A (en) Agent for external application to the skin
UY29051A1 (es) Procedimiento para la preparación de composiciones acuosas de principios activos dificilmente solubles en agua
PL1827109T3 (pl) Zastosowanie naturalnych ekstraktów roślinnych w kompozycjach kosmetyków
CY1108548T1 (el) Βιοπροσκολλητικη γελη βασισμενη σε υδροξυαιθυλοκυτταρινη
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
UA87627C2 (ru) Фармацевтическая композиция в виде тестостеронового геля и ее использование при лечении гипогонадизма у мужчин
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
PA8684501A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
BRPI0409139A (pt) combinação de ingredientes ativos de óleos que contêm ácido graxo w3 com extratos de plantas que contêm polifenol e uso destes
AR046634A1 (es) Una suspension fungicida acuosa concentrada
EA200702496A1 (ru) Местная композиция, содержащая желатин
MA31678B1 (fr) Composition therapeutique aromatisee a base d'argile
UY30198A1 (es) Dominios kunitz quiméricos y su uso
MX9207240A (es) Cateter con punta protegida.
UY29728A1 (es) Forma farmacéutica con liberación sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph.
RU2005136965A (ru) Лечебно-косметическое средство на гелевой основе
WO2006026172A3 (en) Use of soluble cd26 as inhibitor of angiogenesis and inflammation